BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33372039)

  • 21. The p53 pathway and its inactivation in neuroblastoma.
    Tweddle DA; Pearson AD; Haber M; Norris MD; Xue C; Flemming C; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):93-8. PubMed ID: 12880966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
    Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage.
    van der Watt PJ; Leaner VD
    Biochim Biophys Acta; 2011 Jul; 1809(7):316-26. PubMed ID: 21683812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
    Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
    PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.
    Pathria G; Wagner C; Wagner SN
    J Invest Dermatol; 2012 Dec; 132(12):2780-90. PubMed ID: 22832492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.
    Cheng J; Fan YH; Xu X; Zhang H; Dou J; Tang Y; Zhong X; Rojas Y; Yu Y; Zhao Y; Vasudevan SA; Zhang H; Nuchtern JG; Kim ES; Chen X; Lu F; Yang J
    Cell Death Dis; 2014 Feb; 5(2):e1079. PubMed ID: 24556694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.
    Lau L; Hansford LM; Cheng LS; Hang M; Baruchel S; Kaplan DR; Irwin MS
    Oncogene; 2007 Mar; 26(13):1920-31. PubMed ID: 16983334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRM1-dependent p53 nuclear accumulation in lung lesions of a bitransgenic mouse lung tumor model.
    Chen L; Moore JE; Samathanam C; Shao C; Cobos E; Miller MS; Gao W
    Oncol Rep; 2011 Jul; 26(1):223-8. PubMed ID: 21519798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
    Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
    Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
    Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
    Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
    Barbieri E; Mehta P; Chen Z; Zhang L; Slack A; Berg S; Shohet JM
    Mol Cancer Ther; 2006 Sep; 5(9):2358-65. PubMed ID: 16985070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
    Zafar A; Wang W; Liu G; Xian W; McKeon F; Zhou J; Zhang R
    Cancer Lett; 2021 Jan; 496():16-29. PubMed ID: 33007410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53.
    Mao C; Wang X; Liu Y; Wang M; Yan B; Jiang Y; Shi Y; Shen Y; Liu X; Lai W; Yang R; Xiao D; Cheng Y; Liu S; Zhou H; Cao Y; Yu W; Muegge K; Yu H; Tao Y
    Cancer Res; 2018 Jul; 78(13):3484-3496. PubMed ID: 29588351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
    Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
    Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel defect in mitochondrial p53 accumulation following DNA damage confers apoptosis resistance in Ataxia Telangiectasia and Nijmegen Breakage Syndrome T-cells.
    Turinetto V; Porcedda P; Minieri V; Orlando L; Lantelme E; Accomasso L; Amoroso A; De Marchi M; Zannini L; Delia D; Giachino C
    DNA Repair (Amst); 2010 Nov; 9(11):1200-8. PubMed ID: 20947454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
    Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
    Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.